Authors
Latest:
Say Hello to Flexible: Reimagining the Patient JourneyThrough embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.
Latest:
Cold Chain: Delivering Innovative Specialty Pharmaceutical ProductsRafael Teixeira on building an end-to-end cold chain strategy to support global storage and distribution efforts.
Latest:
Doing More With Less: How Automation is Reshaping Drug SafetyBetter technology is redefining pharmacovigilance as it expands beyond its traditional compliance focus to become a key business differentiator.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
How to Rally a Team Around Building a New BusinessThree key components to scaling quickly—while maintaining purpose.
Latest:
Optimizing Pharma Content for Faster Product SubmissionsPharma and life science companies can reduce time to market by optimizing regulatory content management and submission processes.
Latest:
Why Healthcare Costs are Surging—And What to Do About itIdentifying the inflators and deflators, and the role all stakeholders play.
Latest:
Pharma’s Remote Work Cybersecurity ChallengeThe massive shift to remote work has seen pharma companies increasingly targeted by malicious actors seeking out weaker points across the business ecosystem. But with the right mix of technology and mindset, organizations can prepare against threats in the future.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Biotech Companies Deal with Silicon Valley Bank CollapseSilicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
Latest:
A Rare-Disease Must? Building Long-Term RelationshipsThe importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Latest:
All in on AI is Not the Solution in Life Sciences and Health CareAlthough life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.
Latest:
In life sciences, the metaverse opportunity knocksHere are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Latest:
Three Ways Life Sciences Can Educate Stakeholders About BiosimilarsThere are several strategies life sciences companies can use to benefit from biosimilars.
Latest:
Moving Beyond Traditional Approaches to Alzheimer’s DiseaseThe recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
The Silver Lining Of Innovation in Genetic MedicineFailed efforts do not overshadow field’s progress, resolve.
Latest:
Seven Essential Attributes for Investing in Life SciencesThese factors provide investors with enough information to identify promising investment opportunities.
Latest:
Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences OrganizationsExplicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
Latest:
Developing a Product Launch Strategy for an Orphan DrugCommercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Latest:
Optimizing the Value of Real-World Evidence ProjectsMark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.
Latest:
Protecting the Pipeline: Secure Communications Strategies to Thwart Espionage and Safeguard Sensitive Information and Intellectual PropertyIn an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.
Latest:
Navigating PV Divergence: Compliance Tips for New EntrantsWith small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.
